Skip to main content
Journal cover image

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Publication ,  Journal Article
Hershfield, MS; Callaghan, JT; Tassaneeyakul, W; Mushiroda, T; Thorn, CF; Klein, TE; Lee, MTM
Published in: Clin Pharmacol Ther
February 2013

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

February 2013

Volume

93

Issue

2

Start / End Page

153 / 158

Location

United States

Related Subject Headings

  • Stevens-Johnson Syndrome
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Hyperuricemia
  • Humans
  • HLA-B Antigens
  • Gout Suppressants
  • Gout
  • Genotype
  • Dose-Response Relationship, Drug
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E., & Lee, M. T. M. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther, 93(2), 153–158. https://doi.org/10.1038/clpt.2012.209
Hershfield, M. S., J. T. Callaghan, W. Tassaneeyakul, T. Mushiroda, C. F. Thorn, T. E. Klein, and M. T. M. Lee. “Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Clin Pharmacol Ther 93, no. 2 (February 2013): 153–58. https://doi.org/10.1038/clpt.2012.209.
Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153–8.
Hershfield, M. S., et al. “Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Clin Pharmacol Ther, vol. 93, no. 2, Feb. 2013, pp. 153–58. Pubmed, doi:10.1038/clpt.2012.209.
Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MTM. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153–158.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

February 2013

Volume

93

Issue

2

Start / End Page

153 / 158

Location

United States

Related Subject Headings

  • Stevens-Johnson Syndrome
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Hyperuricemia
  • Humans
  • HLA-B Antigens
  • Gout Suppressants
  • Gout
  • Genotype
  • Dose-Response Relationship, Drug